The strength and credibility of the FDA relies on maintaining a clear line between evidence-based, scientific rigor and political priority setting.

While many in the biotechnology sector expressed excitement for faster drug approval timelines, some researchers voiced concerns that critical data review could be missed.

WASHINGTON (AP) — The Food and Drug Administration commissioner's effort to drastically shorten the review of drugs favored by President Donald Trump's administration is causing alarm across the ...

Spruce Biosciences Inc has announced a revised schedule for its regulatory submission of TA-ERT, a potential treatment for Sanfilippo syndrome type B. While the ...

WASHINGTON (AP) — The Food and Drug Administration commissioner’s effort to drastically shorten the review of drugs favored by President Donald Trump’s administration is causing alarm across the ...